Table 1.
Patients' characteristics. Data are expressed as median and quartiles (Q1;Q3) or number (%).
| All patients (n = 16) | HFpEF pathophysiology (n = 5) | Normal (n = 11) | p-value | |
|---|---|---|---|---|
| Age (years) (median (Q1;Q3)) | 68 (63;73) | 75 (72;77) | 65 (61;68) | 0.089 |
| Sex Men/Women (n (%)) | 15/1 (94%/6%) | 4/1 (80%/20%) | 11/0 (100%/0%) | 0.312 |
| Smoking Current (n (%)) | 1 (7%) | 0 | 1 (10%) | 0.592 |
| Smoking Previous (n (%)) | 10 (67%) | 3 (60%) | 7 (70%) | |
| Previous | ||||
| Heart failure | 3 (19%) | 3 (60%) | 0 | 0.018 |
| Atrial fibrillation | 4 (25%) | 2 (40%) | 2 (18%) | 0.547 |
| Myocardial infarction | 1 (7%) | 0 | 1 (10%) | 1.000 |
| Percutaneous coronary intervention | 3 (19%) | 2 (40%) | 1 (10%) | 0.524 |
| CABG | 0 (0%) | 0 | 0 | 1.000 |
| Stroke/TIA | 1 (7%) | 0 | 1 (10%) | 1.000 |
| Peripheral artery disease | 2 (13%) | 2 (40%) | 0 | 0.083 |
| Hypertension | 14 (88%) | 5 (100%) | 9 (82%) | 1.000 |
| Diabetes type 1 type 2 |
8 (50%) 1 (7%) 7 (44%) |
3 (60%) 0 3 (60%) |
5 (45%) 1 (10%) 4 (36%) |
1.000 |
| COPD | 0 (0%) | 0 | 0 | |
| Anemia | 0 (0%) | 0 | 0 | |
| Cancer | 1 (7%) | 0 | 1 (10%) | 1.000 |
| At enrolment (median (Q1;Q3)) | ||||
| BMI | 27 (24;30) | 27 (26;28) | 28 (23;32) | 0.739 |
| Systolic blood pressure (mmHg) | 135 (130;145) | 148 (138;156) | 130 (125;140) | 0.112 |
| Diastolic blood pressure (mmHg) | 80 (75;80) | 83 (73;86) | 80 (75;80) | 0.537 |
| Heart rate (beats/minute) | 66 (57;77) | 66 (51;81) | 66 (63;72) | 0.847 |
| Creatinine (μmol/L) | 82 (75;102) | 84 (76;104) | 79 (74;100) | 0.867 |
| Hb (g/L) | 144 (137;153) | 151 (136;159) | 144 (137;149) | 0.609 |
| Sodium (mmol/L) | 140 (138;141) | 140 (140;141) | 140 (136;141) | 0.733 |
| Potassium (mmol/L) | 4.0 (3.8;4.3) | 3.9 (3.3;4.3) | 4.0 (3.8;4.3) | 0.592 |
| Troponin T (ng/L) | 10 (7;15) | 16 (10;17) | 9 (5;11) | 0.052 |
| NT-proBNP (pmol/L) | 205 (127;367) | 298 (190;697) | 181 (84;338) | 0.090 |
| LDL (mmol/L) | 2.0 (1.5;2.8) | 1.5 (1.4;2.0) | 2.3 (1.5;3.0) | 0.408 |
| Triglycerides (mmol/L) | 1.3 (1.0;2.0) | 1.2 (1.0;1.3) | 1.4 (1.1;2.0) | 0.413 |
| HbA1c (mmol/mol) | 41 (37;46) | 41 (40;46) | 43 (35;46) | 0.780 |
| Urate (μmol/L) | 359 (261;423) | 405 (249;496) | 355 (273;419) | 0.579 |
| Treament (n (%)) | ||||
| Nitrates (long standing) | 8 (50%) | 3 (60%) | 5 (45%) | 1.000 |
| Antiplatelets | 13 (81%) | 5 (100%) | 10 (91%) | 1.000 |
| Anticoagulants | 2 (13%) | 2 (40%) | 0 | 0.083 |
| Betablockers | 15 (94%) | 4 (80%) | 11 (100%) | 0.313 |
| ACE inhibitors | 8 (50%) | 3 (60%) | 5 (45%) | 1.000 |
| ARBs | 10 (63%) | 4 (80%) | 6 (55%) | 0.588 |
| Statins | 16 (100%) | 5 (100%) | 11 (100%) | 1.000 |
| Loop diuretics | 0 (0%) | 0 | 0 | |
| Tiazide diuretics | 4 (25%) | 1 (20%) | 3 (27%) | 1.000 |
ACE = Angiotensin converting enzyme; ARB = Angiotensin II receptor blocker; BMI = Body Mass Index; COPD = Chronic Obstructive Pulmonary Disease; CABG = Coronary Artery Bypass Surgery; NT-proBNP = N-Terminal pro-Brain Natriuretic Peptide; TIA = Transient Ischemic Attack.